Novel Blood Test Predicts Psychotic Disorders Before They Emerge

Schizophrenia, for example, is generally not clinically diagnosed until a person reaches their twenties.

The condition is known to present a number of signs and symptoms than can precede the full-blown psychotic episodes often needed for clinical diagnosis. This early pre-clinical phase of a psychotic disorder is often referred to as the prodromal stage. In the case of schizophrenia, prodromal symptoms appear in nearly three quarters of patients up to five years before the first episode of psychosis occurs.

An international team of molecular psychiatrists led by the Royal College of Surgeons in Ireland (Dublin, Ireland) included in a study a prospective cohort of clinical high-risk (CHR) criteria enable identification of 344 participants recruited across 11 international sites. Protein depletion, digestion, and peptide purification were performed using baseline plasma samples. Prepared sample was injected on a Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham MA, USA) operated in data-dependent acquisition mode for label-free liquid chromatography mass spectrometry. Nine proteins in plasma samples from the same participants were assessed using enzyme-linked immunosorbent assay (ELISA). A cohort of non-high risk individuals were included in the study.

The team used machine learning machine learning, and homed in on a unique pattern of proteins that distinguished those who ultimately went on to develop a psychotic disorder. Ten particular proteins were identified as most predictive, and the test was subsequently validated in a separate dataset. Using the most accurate protein pattern, they were able to correctly determine which high-risk subjects would go on to develop a psychotic disorder by the age of 18 with a 93% accuracy.

The test was less accurate in predicting those high-risk 12-year-olds that did not go on to develop a psychosis by the age of 18. However, considering only between 16% and 35% of young people considered at clinical high risk ultimately transition to a full psychotic disorder, even this low level of accuracy could be useful in stratifying those younger patients more likely to develop psychosis.

David R. Cotter, PhD, a molecular psychiatrist and a senior author of the study, said, “Our study has shown that, with help from machine learning, analysis of protein levels in blood samples can predict who is at truly at risk and could possibly benefit from preventive treatments. We now need to study these markers in other people at high risk of psychosis to confirm these findings.”

The authors concluded that they had developed models incorporating proteomic data predicting transition to psychotic disorder in the CHR state. In a general population sample, several of the same proteins contributed to prediction of psychotic experiences. The study was published on August 26, 2020 in the journal JAMA Psychiatry.